Press Release

Bobcat mRNATM technology is a novel linear mRNA platform able to encode large proteins Data showed restoration of muscular function in DMD mouse model BALTIMORE, March 4, 2024 – Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies using its mRNA platforms, today presented preclinical data on its […]

No safety concerns were observed with EXG‑5003 administration The data suggest a priming effect by EXG-5003 on the long-term cellular immunity of approved SARS-CoV-2 mRNA vaccines. The Company is exploring the use of the c-srRNA platform for the development of vaccines, cell therapies and immunotherapies for several indications BALTIMORE, October 16, 2023 – Elixirgen Therapeutics,

BALTIMORE, January 26, 2023 – Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies using its controllable self-replicating RNA (c-srRNA) platform, today announced that it has entered a memorandum of understanding with Hitachi Global Life Solutions, Inc. (Hitachi GLS) for the development of Micro GMP suites to facilitate

BALTIMORE, Jan. 04, 2023 — Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies using its controllable self-replicating RNA (c-srRNA) platform, today announced that members of the management team will be attending the Biotech Showcase Conference taking place January 9-11, 2023 in San Francisco, California. Akihiro Ko, chief

BALTIMORE, Dec. 21, 2022 — Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies using its controllable self-replicating RNA (c-srRNA) platform, today announced the appointment of Jeffrey L. Cleland, Ph.D., to the Board of Directors to support the advancement of its technology in developing therapies for a broad

Elixirgen Therapeutics Presents New Clinical Data Demonstrating Ex Vivo Telomere Elongation with EXG-34217 in Dyskeratosis Congenita at the 64th ASH Annual Meeting Treatment with EXG-34217 increased the telomere length of CD34+ cells by 1.24-fold ex vivo Telomere flow-FISH study suggests the potential emergence of a cell population with longer telomeres in vivo No acute or

BALTIMORE, November 7, 2022 — Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies using its controllable self-replicating RNA (c-srRNA) platform, today announced an oral presentation of new data showing successful ex vivo telomere elongation with lead asset, EXG-34217 (autologous CD34+ hematopoietic stem cells that have been treated

BALTIMORE, September 7, 2022 — Elixirgen Therapeutics, Inc., a Baltimore-based, clinical-stage biotechnology company focused on the discovery, development, and commercialization of therapies using its controllable srRNA platform, announced today that it has posted a manuscript titled “Controllable self-replicating RNA vaccine delivered intradermally elicits cellular immunity” on the bioRxiv.org preprint server. The link to the preprint

BALTIMORE, March 7, 2022 — Elixirgen Therapeutics, Inc., a Baltimore-based platform biotechnology company focused on the discovery and development of therapies for genetic diseases and vaccines, announced today that it has entered into an exclusive three-year research collaboration agreement with Taisho Pharmaceutical Co., Ltd. The partnership will leverage Elixirgen Therapeutics’ proprietary ZSCAN4 therapy platform to

BALTIMORE, Oct. 8, 2021 — Elixirgen Therapeutics, Inc., a Baltimore-based biotechnology company focused on the discovery and development of therapies for genetic diseases and vaccines, today announced it has entered into an exclusive licensing agreement with a global pharmaceutical company (currently undisclosed) for the rights to commercialize its self-replicating RNA vaccine for COVID-19, called EXG-5003,